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I. Introduction
The completion of the Human Genome Project in 2003, an
international effort to sequence and map all the human genes (known
as the genome),' is considered to be one of the greatest
accomplishments of humankind. Sequencing of 3 billion base pairs of
the human DNA and mapping of roughly 30,000 genes were
completed in less than the projected 15 years at the cost of $3 billion.2
Such a remarkable feat was only possible due to the availability of
numerous tools of biotechnology such as Expressed Sequence Tags
(ESTs), which are small fragments of DNA used to identify genes.'
In 1991, Craig Venter, a molecular biologist at the National Institute
of Health (NIH), surprised the scientific community by announcing
° University of California, Hastings College of the Law, Juris Doctor Candidate 2007;
Ph.D., Molecular Microbiology and Immunology, University of Southern California; B.S.,
Biological Engineering and Sciences, Washington University in St. Louis. I wish to thank
Professor Robin Feldman for her insightful comments.
1. National Human Genome Research Institute, National Institute of Health, All
About the Human Genome Project (HGP), http://www.genome.gov/10001772 (last visited
March 19, 2006).
2. Id.
3. National Human Genome Research Institute, National Institute of Health, ESTs:
Gene Discovery Made Easier [hereinafter ESTs], http://www.ncbi.nlm.nih.gov/About
primer/est.html (last visited March 19, 2006).
that the NIH planned to file for patents on 1,000 ESTs per month.4
The immediate concern was that patents on a crucial tool of the
Human Genome Project would undermine the effort by imposing
additional time and cost.5 Granting patents on ESTs had another
serious far-reaching consequence of effectively placing control of
thousands of genes into the hands of a few patent holders.6
Due to the significant potential adverse impact, the patentability
of ESTs has been a topic of heated debate in intellectual property law
as well as the scientific community. In a recent decision, In re Fisher,7
a divided Federal Circuit upheld the Patent Office's Utility
Guidelines and found that ESTs provide too little real world utility to
be patented. Although this long-awaited decision was anticipated to
settle the question of patentability of ESTs, Fisher may have failed to
establish a decisive standard under which such claims can be
patented. This note analyzes the Fisher decision in light of
constitutional, statutory, precedential, and public interest
considerations and advocates a more explicit and unambiguous
standard for determining the patentability of ESTs. The line dividing
the patentability of ESTs is a thin one that needs to be examined
further and clearly delineated in order to best serve the compelling
future interest of scientific and medical advancement. This note
advocates a focus on the specific utility requirement as well as the
non-obviousness standard for determining the patentability of ESTs,
and further supports the notion of implementing a policy that limits
the scope of the EST patents. In the first section of the note, the
molecular biology of ESTs will be discussed. In the second section,
the history of the patent status will be outlined. The third and fourth
section will discuss the recent Federal Circuit case In re Fisher in
depth and analyze the standard set forth in the decision. In the sixth
section, additional standards for guiding the patentability of ESTs will
be advocated, followed by the conclusion.
II. ESTs: Significance in Biotechnology
To understand the importance and consequence of patentability
of ESTs, a primer on the molecular biology of ESTs would be helpful.
One of the main objectives of the Human Genome Project was to
determine the genomic sequence and establish the complete identity
4. Leslie Roberts, Genome Patent Fight Erupts, 254 Science 184 (1991).
5. Id.
6. Leslie Roberts, NIH Gene Patents, Round Two, 255 Science 912 (1992).
7. In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005).
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of all genes, which are the functional and physical units of heredity
containing information for making specific proteins.8 This was a
compelling objective because such information leads to the ultimate
goal of understanding when, where, and how a gene is activated to
produce proteins, a process known as gene expression.
Understanding gene expression in normal circumstances will allow
scientists to determine the underlying mechanism of altered gene
expression, which controls the development and progression of
various diseases such as cancer."° The limitations in identifying genes
under traditional approaches, such as linkage studies that establish
identity of proximate genes which tend to inherit together," were that
they were intensely laborious and took a great deal of time. 2 The
development of ESTs overcame such limitations by providing
researchers with a quick and inexpensive method for discovering new
genes, obtaining data on gene expression, and constructing genome
13
maps.
ESTs are small fragments of DNA (usually 200 to 500
nucleotides, which are the basic structural building blocks of DNA
that provide information necessary for cellular functions) 4 that serve
as genetic markers or "tags" to fish out the entire genes from the
DNA.15 The underlying premise of gene identification using ESTs
considers following facts. First, the identification of genes in humans
is especially difficult because genome is composed mostly of
nucleotide sequences that are not expressed ("non-coding
sequences") and relatively sparse nucleotide sequences that are
expressed ("coding sequences"), which make up the blue print "code"
for specific genes. 6 Second, gene expression involves excising out the
non-coding sequences that are present within the gene and producing
protein from only the coding sequences. 7 Therefore, by determining
the sequences of just a small portion of these interesting coding parts
8. National Human Genome Research Institute, Definition of a gene,
http://www.genome.gov/glossary.cfm?key=gene (last visited March 19, 2006).
9. ESTs, supra note 3.
10. Id.
11. MedicineNet, Definition of linkage study, http://www.medterns.com/script/mainl
art.asp?articlekey=1 5217 (last visited March 19, 2006).
12. Id.
13. Id.
14. PETER SNUSTAD & MICHAEL J. SIMMONS, PRINCIPLES OF GENETICS 209-12 (3d
ed. 2003).
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of a gene, researchers are able to produce the corresponding EST to
fish out and identify the entire gene. 8
ESTs have been proven as powerful tools, not only in the
sequencing and identification of genes in the Human Genome
Project, but also in the search for genes involved in hereditary
diseases and cancer.' 9 Scientists have used ESTs that correspond to
disease gene candidates to examine the DNA of patients to isolate
the genes.20  This method has already aided in isolating genes
involved in Alzheimer's disease, colon cancer, and many other
diseases.2' It is undeniable that ESTs have powerful utility in
biotechnology and genetic research.
1I. History of Patent Status of ESTs
Despite such utility in biotechnology, ESTs' patentability has
been an uncertain issue. In Diamond v. Chakrabarty, the Supreme
Court pointed out that "anything under the sun made by man" is
patentable subject matter.22 In considering the validity of a patent for
genetically modified bacteria, the Supreme Court validated the
patentability of "non-naturally occurring" living things under 35
U.S.C. § 101 of the Patent Act.' This notion that patentable subject
matter includes things found in nature that has been modified to vary
from the naturally occurring form can be traced to Parke-Davis v.
Mulford, which granted a patent on a purified hormone isolated from
adrenal glands of cadavers.24 Following these interpretations, purified
natural proteins and purified DNA sequences were recognized as
patentable subject matter in Amgen v. Chugai Phamaceutical.z
Significantly, the Amgen court required that a gene be described by
its structure, specific description of the nucleic acid sequences, and
not by its function.26 This principle was reaffirmed in subsequent
cases, Fiers v. Revel and Regents of University of California v. Eli





22. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
23. Id.
24. Parke-Davis Co. v. H. K. Mulford Co., 189 F. 95 103 (C.C.S.D.N.Y. 1911), affd
196 F. 496 (2d. Cir. 1912).
25. Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1218 (Fed. Cir. 1991).
26. Id. at 1214.
27. Fiers v. Revel, 984 F.2d 1164 (Fed. Cir. 1993); Regents of Univ. of Cal. v. Eli Lilly,
119 F.3d 1559 (Fed. Cir. 1997).
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Shortly after describing ESTs as a promising new method for
sequencing the human genome in 1991, Craig Venter and other
researchers at the NIH filed the first patent applications for ESTs,
provoking heated controversy among scientists." Hoping to maintain
open and free access to genomic information and materials,
biomedical researchers and patient advocates protested against
granting EST patents by asserting that EST patents did not meet the
utility requirement.29
Despite such protests, in 1998, the first EST patent was issued to
Incyte Pharmaceuticals, Inc. for "Human Kinase Homologs" (U.S.
Patent No. 5,817,479) that were based on 12 EST sequences claimed
to predict the function of the genes from which the ESTs were
derived.' The patent states that the nucleotide sequences may be
used in molecular biology techniques that have not yet been
developed, to generate probes for mapping the native genomic
sequence, to design the oligonucleotide primers for the extension of
cDNA to full length, or to produce a kinase kit for diagnosing
disorders or diseases associated with altered kinase expression."
In 1999, partly in response to the continuing questions about the
patentability of ESTs, the United States Patent and Trademark Office
(USPTO) drafted proposed guidelines for determining whether
inventions met the utility requirement, and requested comments from
the public. 32 Echoing the holdings from the 1966 Supreme Court case
of Brenner v. Manson, Bruce Alberts, then President of the National
Academies of Science, argued:
Those who would patent human DNA sequences without real
knowledge of their utility are staking claims not only to what little
they know at the moment, but also to everything that might later be
discovered about the genes and proteins associated with the
sequence. They are, in effect, laying claim to a function or use that
does not yet exist.
33
In 2001, the USPTO implemented the finalized Utility
Examination Guidelines, which incorporated a higher utility standard
28. Paula K. Davis, et. al., ESTs Stumble at the Utility Threshold, 23 Nature
Biotechnology 1227 (2005).
29. Id.
30. Cynthia D. Lopez-Beverage, Should Congress Do Something About Upstream
Clogging Caused By The Deficient Utility of The Expressed Sequence Tag Patents, 10 J.
TECH. L. & POL. 35, 84 (2005).
31. Id. at 84-85.
32. Id.
33. Id.
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requiring specific, substantial, and credible utility,' and began to
reject EST patent applications.35 In re Fisher represents the first
appeal of such a rejection.
IV. In re Fisher
Not surprisingly, the first appeal before the Federal Circuit
involving ESTs has attracted considerable interest from the scientific
and legal communities alike. A number of scientific and academic
organizations as well as biotechnology and pharmaceutical companies
submitted amicus briefs.36 The potential impact that would result
from the case made it a highly anticipated decision in patent law as
well as in the scientific community.
In Fisher, Monsanto scientists Dane Fisher and Raghunath
Lalgudi filed a patent application that disclosed approximately 32,000
specific nucleotide sequences for ESTS from various maize tissues.37
During patent prosecution, the USPTO restricted Monsanto to five
ESTs3". Monsanto's final claimed invention consisted of five ESTs
corresponding to genes expressed from the maize pooled leaf tissue at
the time of anthesis39 (pollination stage)'. The application specified
that the ESTs can enable the acquisition of molecular markers, which
can be used in breeding schemes, genetic and molecular mapping, and
the cloning of agronomically significant genes." Nevertheless, the
application failed to disclose any information about coding sequences
associated with these ESTs or about the proteins they encode. The
only claim in the application read: "A substantially purified nucleic
acid molecule that encodes a maize protein or fragment thereof
comprising a nucleic acid sequence selected from the group consisting
34. Utility Examination Guidelines, 66 Fed. Reg. 1092, 1094 (2001) [hereinafter
Utility Guidelines].
35. Davis, et. al., supra note 30, at 1227.
36.. Fisher, 421 F.3d at 1365.
37. Ex parte Fisher, 72 U.S.P.Q.2d 1020 (BPAI 2004), available at
http://patentlaw.typepad.com/patent/Ex_20Parte_20Fisher.pdf.
38. Id.
39. Fisher, 421 F.3d at 1368.
40. The term "anthesis" encompasses the period from the first pollen grain shed until
the last fruit set. See R.J. Salvador and R.B. Pearce, Proposed Standard System of
Nomenclature for Maize Grain Filling Events and Concepts, MAYDICA 40(2): 141-46,
available at http://www.public.iastate.edu/-rjsalvad/manuscripts/nomenclature/
nomenclature.html.
41. Fisher, 72 U.S.P.Q.2d at 1020.
42. Fisher, 421 F.3d at 1368.
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of SEQ ID NO: 1 through SEQ ID NO: 5. ' 3 The application
generally disclosed that the five claimed ESTs may be used in a
variety of ways, including: (1) serving as a molecular marker for
mapping the entire maize genome, which consists of ten
chromosomes that collectively encompass roughly 50,000 genes; (2)
measuring the level of mRNA in a tissue sample via microarray
technology (method of studying how large numbers of genes interact
with each other)' to provide information about gene expression; (3)
providing a source for primers for use in the polymerase chain
reaction ("PCR," which is a technique for making an unlimited
number of copies of any piece of DNA)45 process to enable rapid and
inexpensive duplication of specific genes; (4) identifying the presence
or absence of a polymorphism (a common variation in the sequence
of DNA among individuals);' (5) isolating promoters (the part of a
gene that contains the information to turn the gene on or off)4 7 via
chromosome walking (a technique which produces sets of overlapping
DNA clones for studying segments of DNA larger than can be cloned
individually);' (6) controlling protein expression; and (7) locating
genetic molecules of other plants and organisms.
4 9
The USPTO rejected claim 1 and refused to grant the patent on
the grounds that the claimed ESTs have no specific and substantial
utility. 0 The ESTs were concluded to lack specific utility because
they can only be used to locate genes of unknown function, as can all
other ESTs.5" Furthermore, the ESTs lacked substantial utility
because there was no known 'real world' use for the proteins
produced as final products resulting from the ESTs. 2  As a direct
43. Id. at 1367.
44. National Human Genome Research Institute, Definition of microarray
technology, http://www.genome.gov/glossary.cfm?key=microarray+technology (last visited
March 19, 2006).
45. National Human Genome Research Institute, Definition of PCR,
http://www.genome.gov/glossary.cfm?key=polymerase%20chain%20reaction%20(pcr)
(last visited March 19, 2006).
46. National Human Genome Research Institute, Definition of a polymorphism,
http://www.genome.gov/glossary.cfm?key=polymorphism (last visited March 19, 2006).
47. National Human Genome Research Institute, Definition of a promoter,
http://www.genome.gov/glossary.cfm?key=promoter (last visited March 19, 2006).
48. Northwestern University Department of Biochemistry, Definition of chromosome
walking, http://www.biochem.northwestern.edu/holmgren/Glossary/Definitions/Def-
C/chromosomewalking.html (last visited March 19, 2006).





consequence of the utility rejection, the application was also rejected
on the basis of a lack of enablement
5 3
Monsanto appealed the rejection of its patent application to the
USPTO's Board of Patent Appeals and Interferences, which
considered each of Monsanto's seven potential uses, although
Monsanto focused its appeal on only two: (1) use for the
identification of polymorphisms; and (2) use as probes or as a source
for primers.' The Board affirmed the rejection for lack of utility by
reasoning that the application failed to explain the usefulness of the
potential uses, which approached the "insubstantial use" end of the
spectrum. 55
On appeal to the United States Court of Appeals for the Federal
Circuit (Federal Circuit), Monsanto argued that the USPTO is
applying a higher utility standard than stipulated by law and contends
that the congressional intent of Title 35 U.S.C.A. section 101
emphasizes a much lower standard 6 The government rebutted this
argument by claiming that a patent applicant is required to disclose
only a single specific and substantial utility pursuant to Brenner and
the USPTO's Utility Guidelines, and Monsanto failed in this task
because the alleged uses for the ESTs are so general as to be
meaningless. 7
In affirming the Board's rejection of Monsanto's application, the
Federal Circuit looked to the Supreme Court's utility standard
announced in Brenner. In Brenner, the Supreme Court explained
what is required to establish the usefulness of a new invention by
stating:
The basic quid pro quo contemplated by the Constitution and the
Congress for granting a patent monopoly is the benefit derived by
the public from an invention with substantial utility. Unless and
until a process is refined and developed to this point-where
specific benefit exists in currently available form-there is
insufficient justification for permitting an applicant to engross what
may prove to be a broad field."
The Federal Circuit pointed out that although the Supreme
Court has not precisely defined "specific" and "substantial," courts
have provided guidance to the meaning of the terms. 9 To satisfy the
53. Id.
54. Id.
55. Id. at 1368-89.
56. Id. at 1369.
57. Id. at 1370.
58. Brenner v. Manson, 383 U.S. 519, 534-35 (1966).
59. Fisher, 421 F.3d at 1371.
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"substantial" utility requirement, a claimed use must show that the
invention has a significant and presently available or a "real world"
benefit to the public. 60 To meet "specific" utility, an invention must
disclose a use which is not so vague to be meaningless.61 For example,
using an EST to produce a kit for diagnosing disorders or diseases
associated with altered expression of the corresponding gene has
been determined to meet the specific utility requirement.62 The
Federal Circuit concluded that the claimed ESTs act as no more than
research intermediates that may help scientists to isolate the
particular underlying protein-encoding genes, especially since
Monsanto admits that the underlying genes have no known
functions." Nevertheless, Monsanto argued that a research tool such
as an EST is analogous to a microscope because both are useful in
generating data from samples having unknown properties.' 4 The
Federal Circuit, however, found Monsanto's analogy to be flawed
because unlike a microscope which has specific benefit of magnifying
objects to immediately reveal the structure, ESTs can only be used to
detect objects having the same structure as the EST itself without
providing any information about structure or function of the
associated gene.65 Moreover, the Federal Circuit further concluded
that Monsanto's asserted uses for the ESTs represent merely
hypothetical possibilities. 6
V. Fisher Analysis
Although the judgment in Fisher was decided correctly for the
facts specific to the case, it may have failed to provide a definitive
standard for the patentability of ESTs. The Federal Circuit upheld
the USPTO's heightened utility standard of specific and substantial
utility by relying on Brenner's holding that research intermediates do
not meet such standard.67 This rationale may be unsound because it
neglects to properly consider the unique nature of ESTs and




62. Lopez-Beverage, supra note 30, at 84-85.




67. Id. at 1371.
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A. Substantial Utility
The majority opinion in Fisher heavily emphasizes the
requirement of substantial utility for patentability of ESTs. This
emphasis may be flawed for two reasons. First, the Federal Circuit's
reliance on the Brenner Court's holding may not be well placed
because Brenner is distinguishable. The Federal Circuit specifically
notes that the USPTO analogized the current facts to those in
Brenner, in which an applicant claimed a process of making a
compound having no known use. 68 According to the USPTO's Utility
Examination Guidelines, "substantial use" is at least one available
practical benefit to the public. 69  Unlike the steroid compound
without any known use in Brenner, ESTs do have substantial or "real
world" utility that provides immediate benefits to the public. In 1995,
the USPTO's then-leading expert in biotechnology, Associate
Solicitor Scott Chambers argued:
[I]f the patent applicant provide[s] precise chromosomal map
locations for each of the EST fragments, sufficient utility for 35
U.S.C. §101 might be present. Numerous scientific articles have
stated that precise marker locations are very important to the
Human Genome Project ('HGP'). This project represents 3-5
billion dollar market. Any element that is fundamental to a $3
billion market has utility.7"
Chambers noted that the use of EST markers as genetic probes
satisfies the section 101 utility requirement, reasoning that making a
large number of probes available to researchers allows quick
identification of probes that "correlate closely with the disease locus,
speeding the development of diagnostic probes."7 Indeed, ESTs
have been instrumental in the successful completion of the Human
Genome Project ahead of schedule.'
Furthermore, unlike chemicals whose only utility depends upon
the actual exhibition of biological activity, ESTs can be used as
probes, whether they ultimately find a target or not.73  Such
distinguishing characteristics of ESTs are illustrated by the fact that a
probe that successfully locates a gene that codes for a specific protein
68. Id. at 1369.
69. Utility Guidelines, supra note 34, at 1094.
70. Harold C. Wegner, Article: Development in Patent Law 2004, 4 J. MARSHALL
REV. INTELL. PROP. L. 1, 28-29 (2004).
71. Id.
72. Mark S. Boguski, The Turning Point in Genome Research, Trends in Biochemical
Sciences, 20: 295-96 (1995), available at http://www.dur.ac.uk/stat.web/Bioinformatics/
ESTdatabase.html.
73. iBrieflHealth & Biotechnology, The Fate of Gene Patents Under the New Utility
Guidelines, 2001 DUKE L. & TECH. REV. 0008, 1 21 (2001) [hereinafter Fate].
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has performed its task, regardless of how the protein functions in a
living system. 4 Moreover, ESTs are useful as molecular markers on
physical or genetic maps regardless of what is known about the
function of the corresponding gene." Therefore, Monsanto's claimed
use that its ESTs serve as a molecular marker for mapping the entire
maize genome is a credible and significant use.
Also, the rejection of research intermediates used for further
study of its own utility without "immediate benefit" is inconsistent
with the USPTO's grant of patents to such products. Patents have
been granted for products with anti-tumor effectiveness
demonstrated only in laboratory animals, where the animals
themselves were mere objects of scientific research.76 For example,
the "Harvard Mouse," a genetically engineered mouse with a gene
that causes breast cancer in mammals, arguably is solely a research
intermediate without an "immediate benefit" since its only usefulness
derives from conducting research.77 Nevertheless, the "substantial
utility" of testing carcinogens and compounds that confer protection
against cancer in these mice was recognized as significant.78 Other
cases have similarly found sufficient utility even where the invention
could not readily be used by anyone.79 It is certainly true that many
compounds shown to be useful solely by animal testing are not
immediately beneficial.i ° Yet, the Federal Circuit has previously
rationalized that therapeutics and other inventions with uses
established solely through animal studies are patentable because they
will "marshal sources and direct the expenditure of effort to further in
vivo testing of the most potent compounds, thereby providing an
immediate benefit to the public."8'  Arguably, the same reasoning
could apply to ESTs since the identification of genes through the use
of ESTs lead to further effort to characterize and understand genes,
which would confer a significant immediate benefit to the public.
Thus, the ESTs' function as research intermediates should not play a
role in the evaluation of their utility. The dissent further supports this
74. Id.
75. William F. Lee, et. al., Limits on Patentability in Life Sciences: Claims Covering
Expressed Sequence Tags, 6 SEDONA CONF. J. 95, 99 (2005).
76. Fate, supra note 73, at 26.
77. Michael B. Landau, Multicellular Vertebrate Mammals as "Patentable Subject
Matter" Under 35 U.S.C. § 101: Promotion of Science and the Useful Arts or an Open
Invitation for Abuse?, 97 DICK. L. REV. 203, 213-14 (1993).
78. Id. at 214-15.
79. Fate, supra note 73, at 26.
80. Id.
81. Id. (quoting Cross v. lizuka, 753 F.2d 1040, 1051 (Fed. Cir. 1985)).
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notion by arguing that the majority failed to understand the complex
nature of scientific discovery, and that under the majority's holding
"only the final step of a lengthy incremental research gets
protection." '
Second, the Federal Circuit indicated that the claimed ESTs did
not meet the utility requirement because Monsanto did not identify
the function for the underlying protein-encoding genes. 83 However,
such requirement of characterization of genes and proteins may have
under-inclusive consequences and encounter the concerns associated
with the "one embodiment doctrine, ' which further complicate the
standard of patentability. Under-inclusiveness would result when an
EST has a significant utility without a corresponding characterized
gene or protein. Indeed, the Utility Guidelines suggest that the utility
of a claimed DNA does not necessarily depend on the function of the
encoded gene product.8 ' Even if the gene product itself is not known,
an EST that "hybridizes near a disease-associated gene or has a gene-
regulating activity" may have a specific and substantial utility.
86
Certainly, the ESTs that have yielded the identity of genes involved in
diseases such as Alzheimer's disease' and colon cancer8 would have
substantial utility under the Utility Guidelines. Also, DNA fragments
that have gene regulating activity8 9 would be sufficient to meet the
utility standard under the Utility Guidelines. In fact, one of the
claimed uses of Monsanto's ESTs is to control protein expression. 90
82. Fisher, 421 F.3d at 1380.
83. Id. at 1376.
84. Robin Feldman, Rethinking Rights in Biospace, 79 S. CAL. L. REV. 1, 9-10 (2005).
85. Utility Guidelines, supra note 34, at 1095.
86. Id.
87. See Mark D. Adams, et. al., Rapid cDNA Sequencing (Expressed Sequence Tags)
From a Directionally Cloned Human Infant Brain cDNA Library, 4 NATURE GENETICS
373 (1993). A human infant brain cDNA library, made specifically for production of ESTs
yielded two proteins similar to the Alzheimer's disease amyloid precursor protein.
88. See Nickolas Papadopoulos, et. al., Mutation of a mutL Homolog in Hereditary
Colon Cancer, SCIENCE 263 (5153): 1625-29 (1994). A search of a large database of ESTs
derived from random cDNA clones revealed three additional human mismatch repair
genes, all related to the bacterial mutL gene. One of these genes (hMLH1) was linked to
cancer susceptibility in hereditary nonpolyposis colorectal cancer.
89. See Shyam Ramchandani, et. al., Inhibition of Tumorigenesis by a Cytosine-DNA,
Methyltransferase, Antisense Oligodeoxynucleotide, PROC. NATL. ACAD. Sc. 94(2): 684-
89 (1997) (testing the hypothesis that cytosine DNA methyltransferase (DNA MeTase) is
a candidate target for anticancer therapy, the authors show that a phosphorothioate-
modified, antisense oligodeoxynucleotide directed against the DNA MeTase mRNA
reduces the level of DNA MeTase mRNA, inhibits DNA MeTase activity, and inhibits
anchorage independent growth of Y1 adrenocortical carcinoma cells ex vivo in a dose-
dependent manner).
90. Fisher, 421 F.3d at 1368.
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The problem with this claim is that it is merely a hypothetical and not
a demonstrated claim.91 However, it should be noted that, as the
dissent points out, "the Board did not reject Monsanto's utilities on
the basis that the ESTs were unable to perform the purported
utilities." 92 Therefore, it is uncertain whether the patent would have
been granted if Monsanto demonstrated the gene regulation claim
without characterizing the corresponding target genes of the ESTs. It
is equally uncertain whether the Federal Circuit would view such
scenario as meeting the substantial utility under Fisher, which would
not grant EST patents without the characterization of the
corresponding gene. Therefore, a less ambiguous interpretation of
the utility standard would be to evaluate function regardless of
whether the gene is characterized or not.
Also, the requirement of identification and characterization of
genes or proteins provide a false sense of substantial utility because of
the concerns associated with the "one embodiment doctrine." 93 The
doctrine asserts that once the inventor identifies a single use for the
product, the inventor may exclude others from the full range of its
use, including any other embodiments of the product.9 For example,
if an applicant is granted a patent for an EST with a description of
corresponding gene or protein function that is minimal, it could
potentially penalize a subsequent researcher that discovers a
groundbreaking utility for the EST or the gene, such as the treatment
of a disease. Indeed, a recent gene patent illustrates this point. The
USPTO issued a patent to Human Genome Sciences (HGS) that
claimed the gene for CCR5, a receptor that binds protein molecules
termed "chemokines" at the surface of CD4+ leukocyte cells.9 The
patent was on the CCR5 gene, its protein, and fragments of DNA for
locating the gene.' However, the patent does not disclose the
function of the particular claimed protein. 97  Subsequent to the
patenting of CCR5 gene, it was discovered to have potential
therapeutic use for HIV/AIDS.9 8 But when it applied for the patent,
HGS was not aware that CCR5 had any connection to AIDS, or that
it was possibly the first step toward developing a cellular "block"
91. Id. at 1373.
92. Id. at 1381.
93. Feldman, supra note 84, at 9-10.
94. Id.
95. Fate, supra note 73, at 6.
96. Id.
97. Id.
98. Lopez-Beverage, supra note 30, at 84.
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against HIV.' In fact, contrary to this discovery, the patent
application for the CCR5 gene claimed its utility could be a receptor
for a virus, which is a general claim that could be made for any cell
surface molecule. 10
In consideration of such concerns associated with the one
embodiment doctrine, the USPTO was advised to include a standard
that limits "speculative uses of DNA that were not foreseen at the
time of the application.' 0' The USPTO rejected the adoption of such
a standard because it is inconsistent with the patent statute that only
one utility is required to be demonstrated to qualify for a patent.1°2
This policy may arguably be equitable when a single product
invention, such as a therapeutic drug, is found to have a different
utility subsequent to the original patent application. ESTs, on the
other hand, are different products that function entirely differently
from their corresponding genes and proteins. Therefore, allowing the
patent holder of an EST to control the unidentified protein that
corresponds to the claimed gene grants undue rights that is unfair to
the subsequent researchers, and furthermore does not "promote the
Progress of Science and useful Arts" contemplated by the
Constitution" since it provides a disincentive to further research.
Accordingly, the scope of patent rights should be limited.
Application of a "limitation in scope policy" to EST patents could
prevent granting of rights far in excess to the inventive disclosure,
which is one of the major policy concerns surrounding the
patentability of ESTs.'4 Without such policy concerns revolving the
one embodiment doctrine, the patentability of ESTs could come
under more objective scrutiny.
B. Specific Utility
The majority in Fisher also concluded that Monsanto's ESTs
lacked specific utility.'O° The Federal Circuit analogizes Monsanto's
"laundry list" of claimed uses to the nebulous terms like "biological
activity" or "biological properties" that were under contention in In
re Kirk.'06 However, this analogy and reasoning is faulty in that the
99. Id.
100. Id.
101. Utility Guidelines, supra note 34, at 1095, comment 11.
102. Id.
103. U.S. Const. art. I, § 8, cl. 8.
104. Utility Guidelines, supra note 34, at 1095, comment 11.
105. Fisher, 421 F.3d at 1374.
106. In re Kirk, 376 F2.d 936, 941 (C.C.P.A. 1967).
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vague terms like "biological activity" and "biological properties" is
not equivalent in specificity to descriptions such as "serving as a
molecular marker for mapping the entire maize genome, which
consist of ten chromosomes that collectively encompass roughly
50,000 genes"'0 7 or "measuring the level of mRNA in a tissue sample
via microarray technology to provide information about gene
expression. "' Monsanto's claimed uses are specific applications of
molecular biology'0° and do not encompass the entire field of practice
as the terms used in Kirk. Moreover, the Federal Circuit concludes
that the claimed uses lack specific utility because any EST transcribed
from any gene in the maize genome has the potential to perform any
one of the alleged uses."0 While this is true, the real problem with
Monsanto's claimed uses stems from a lack of specific context rather
than the actual described uses.
For example, the described uses may have specific utility if
Monsanto framed a specific context of identification of gene
expression at the time of anthesis around the claimed uses. The
Federal Circuit correctly points out that the application failed to show
that the claimed ESTs would be expressed only during anthesis or
that they would be capable of isolating a promoter active in maize
leaves at the time of anthesis."' If, however, Monsanto demonstrated
that the claimed ESTs could identify maize genes exclusively
expressed during anthesis, they would have a valuable utility in
identifying or screening for anthesis in maize or possibly other related
plants regardless of the identity of those genes. Then the claimed use
of "measuring the level of mRNA in a tissue sample via microarray
technology to provide information about gene expression" 2 would
have a specific utility due to the specific context of anthesis detection.
Although the rationale in Fisher is flawed, specific utility should
be one of the main emphases in the standard for determining
patentability of ESTs. Moreover, the focus should be on the specific
context of the claimed uses.
107. Fisher, 421 F.3d at 1368.
108. Id.
109. Snustad, supra note 14, at 518-27.
110. Fisher, 421 F.3d at 1374.
111. Id. at 1369.
112. Id. at 1368.
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VI. Additional Standard of Non-obviousness
In addition to the specific utility standard, the standard of non-
obviousness should be applied when evaluating the patentability of
ESTs. The USPTO was urged to consider that sequencing DNA has
become so routine that determining the sequence of a DNA molecule
is not inventive."' The Human Genome Organization (HUGO)
advocates that ESTs are obvious and thie creation of ESTs does not
involve any inventive step.114 The current strategy of large-scale EST
sequencing represents a straightforward extension of a technique that
has been in use on a smaller scale for years."5 The scientific work
involved in generating ESTs is straightforward and based on
automated sequencing technology. 116 After learning of initial
attempts to patent ESTs, James Watson"7 was purported to saying
that allowing patents on ESTs was "pure lunacy" and further
commented that "virtually any monkey" could run the automated
sequencing machines."8 Nevertheless, the USPTO rejected such
suggestion by citing 35 U.S.C. 103(a): "Patentability shall not be
negatived by the manner in which the invention was made.' 1 9
Instead, whether a claimed DNA would have been obvious depends
on whether a molecule having the particular structure of the DNA
would have been obvious to one of ordinary skill in the art at the time
the invention was made.1 20 Therefore, taken together, the sequence
of the gene itself must be obvious, and the method for determining
the sequence is irrelevant to the non-obviousness evaluation in gene
patents. 121
The issue of non-obviousness for patentability of ESTs has
significantly been affected by the publication of the sequence of the
113. Utility Guidelines, supra note 34, at 1095, comment 13.
114. Leslie G. Restaino, et. al., Patenting DNA-Related Inventions in the European
Union, United States and Japan: A Trilateral Approach or a Study In Contrast?, 2003
UCLA J. L. & TECH. 2 (2003).
115. Id.
116. Id.
117. James Watson is one of the co-discoverers of the structure of DNA. See J.D.
Watson & F.H.C. Crick, Molecular Structure of Nucleic Acids, 4356 NATURE 737, 737
(1953).
118. Lopez-Beverage, supra note 30, at 77.
119. Id.
120. Id. (citing In re Deuel, 51 F.3d 1552, 1559 (Fed. Cir. 1995) and In re Bell, 991 F.2d
781 (Fed. Cir. 1993)).
121. M. Scott McBride, Patentability of Human Genes: Our Patent System Can Address
the Issues Without Modification, 85 MARQ. L. REV. 511, 522 (2001).
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human genome in 2001.122 Since the Federal Circuit has defined the
patentability of gene by its DNA sequence, it is apparent that the
publication of the complete human genome results in the
unpatentability of all human genes described in the publication for
failing the novelty test of 35 U.S.C. § 102(b).' 3 Therefore, claims to
naturally occurring human genes or gene fragments in applications
submitted after February 16, 2002' are unpatentable for lack of
novelty. 124 Such claims must rely instead on the patentability of some
downstream product of the gene or gene fragment.12 ' However, gene
variants, mutants, polymorphisms not described in the human
genome publication remain patentable as long as they are not
obvious. 126
Furthermore, in 1992 scientists at NCBI developed a new
database to catalogue ESTs.'2 Once an EST that was submitted to
GenBank, the NIH sequence database operated by National Center
for Biotechnology Information(NCBI), had been screened and
annotated, it was then deposited in this new database, called dbEST.
NCBI scientists annotate the EST database record with any known
information.18 For example, if an EST matches a DNA sequence that
codes for a known gene with a known function, that gene's name and
function are placed on the EST record. 2 9  Therefore, with
increasingly more information about ESTs and their corresponding
genes accumulating in the public database, it would be more difficult
to meet the novelty and obviousness requirement for patenting
ESTs.' 3
Moreover, a patent applicant would not be able to circumvent an
obviousness rejection by claiming that there is unpredictability in the
function or knowledge of specific ESTs. In In re O'Farrell, the
USPTO rejected the application based on 35 U.S.C. § 103
obviousness because of prior art references disclosing techniques for
122. J.C. Venter et. al., The Sequence of the Human Genome, 291 SCIENCE 1304, 1305-
51(2001).
123. Robert S. Schwartz, Genes For Free: The Effect of Publication of the Human
Genome on the Patentability of Genes and Gene-Based Inventions, 23 PACE L. REV. 731,
745 (2003).
124. Id. at 746. February 16, 2002 represents one year after the publication of the
complete sequence of the human genome.
125. Id.
126. Schwartz, supra note 123, at 746.
127. ESTs, supra note 3.
128. Id.
129. Id.
130. See generally Schwartz, supra note 123.
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producing recombinant proteins.13 ' The inventors asserted that the
claimed invention could not have been obvious due to the significant
unpredictability in the field molecular biology at the time of the
patent application.132 Nevertheless, the court rejected this argument
because rather than unpredictability, non-obviousness analysis
depended on whether a person of ordinary skill in the art would have
considered that prior art techniques employed were likely to
succeed.3  Thus, presumably the only ESTs that could meet the
novelty and non-obviousness standard currently are the ones that
have not been published either in the complete sequence of the
human genome or in the public EST database, and a person of
ordinary skill in molecular biology would not have considered that
prior art techniques employed were likely to succeed. This would
effectively eliminate most of the ESTs and leave patents to truly
unique and unanticipated ESTs.
VI.Conclusion
Francis Collins, the director of the Human Genome Project, has
expressed concern that putting "toll booths on basic science" will
stifle the very progress gene patents should encourage.34 In Fisher,
Monsanto argued that such policy concerns that awarding patents on
ESTs would inhibit innovation is no basis for rejecting them if the law
says otherwise, even if it would be "bad public policy."' 35 The court
did not agree with the concerns raised by the government and certain
amici that allowing EST patents without proof of utility would
discourage research, delay scientific discovery, and thwart progress in
the "useful Arts" and "Science." The court took the view that
Congress did not intend for these practical implications to affect the
determination of whether an invention satisfies the requirements set
forth in 35 U.S.C. §§ 101, 102, 103, and 112.' 6
Although the patentability of genes and gene fragments such as
ESTs has serious economic, social, and medical implications,
ultimately it is a matter of law. The Constitution, statute, and case
law have converged to allow patents on genes and gene fragments, as
long as they meet the requisite conditions. In re Fisher, the first case
131. In re O'Farrell, 853 F.2d 894, 895 (Fed. Cir. 1988).
132. Id. at 902.
133. Id. at 903.
134. Laurie L. Hill, The Race to Patent the Genome: Free Riders, Hold Ups, and the
Future of Medical Breakthroughs, 11 TEX. INTELL. PROP. L. J. 221, 241 (2003).
135. See Fisher, 421 F.3d at 1365.
136. Id. at 1378.
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heard by the Federal Circuit on the patentability of ESTs, represents
a piece of that instruction. The court's application of the standard of
specific and substantial utility in this case, however, may have missed
the mark due to the underlying complexity of the technology. The
unique nature of genetic inventions, such as ESTs, requires a more
unambiguous standard, which analyzes the utility, non-obviousness,
and novelty in light of the current advancement in the art.
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